Treatment of non-Hodgkin's lymphoma

Anti-Cancer Drugs

Volumn 9, Issue 10, 1998, Pages 879-888

  Dranitsaris, Gorge ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Non Hodgkin's lymphoma; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; HISTOLOGY; HUMAN; NONHODGKIN LYMPHOMA; NORTH AMERICA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0032436769     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199811000-00007     Document Type: Article

References (94)

1. American Cancer Society. Cancer facts and figures 1992. New York: American Cancer Society 1992: 4.
2. Silverberg E, Boring CC, Squires T. Cancer Statistics 1990. CA Cancer J Clin 1990: 7-24.
3. Weisenburger DD. Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 1994; 5 (suppl 1): 19-24.
4. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-35.
5. Lee Harris N, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
6. Bierman PJ, Vose JM, Armitage JO. Clinical manifestations, staging, and treatment of Non-Hodgkin's Lymphoma. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, eds. Hematology: basic principles and practice of oncology. New York: Churchill Livingston 1991: 963-90.
7. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1023-30.
8. Cowan RA, Harris M, Jones M, et al. DNA content in high and intermediate grade non-Hodgkin's lymphoma: prognostic significance and clinicopathological correlations. Br J Cancer 1989; 60: 904-10.
9. Hoskins PJ, Ng V, Spinelli JJ, et al. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 1991; 9: 220-6.
10. Salles G, Shipp MA, Coiffier B. Chemotherapy of non-Hodgkin's agressive lymphomas. Semin Hematol 1994; 31: 46-69.
11. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-9 4.
12. Sweet DL, Kinzie J, Gaeke MK, Golomb HM, Ferguson DL, Ultman JE. Survival of patients with localized diffuse histiocytic lymphoma. Blood 1981; 58: 1218-23.
13. Connors JM, Klimo P, Fairey RN, Voss N. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Meet 1987; 107: 25-30.
14. Longo DL, Glatstein E, Duffey PI, et al. Treatment of localized agressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 1989; 7: 1295-302.
15. Krikorian JG, Portlock CS, Cooney P, Rosenberg SA. Spontaneous regression on non-Hodgkin's lymphoma: a report of nine cases. Cancer 1980; 46: 2093-9.
16. McLaughJin P, Fuller LM, Velasquez WS, et al. Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 1987; 5: 867-74.
17. Smalley RV, Anderson JW, Hawkins MJ, et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1336-41.
18. Coltman CA, Dahlberg S, Jones SE, et al. CHOP is active in thirty percent of patients with large cell lymphoma: a twelve year Southwest Oncology Group follow up. In: Skarin AT, ed. Advances in cancer chemotherapy: update on treatment for diffuse large cell lymphoma. New York: Park Row 1986: 71-7.
19. Coleman M. Chemotherapy for large-cell lymphoma: optimism and caution. Ann Intern Med 1985; 103: 140-2.
20. Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann intern Med 1986; 104: 757-65.
21. Gordon LI, Harrington D, Anderson J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342-9.
22. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
23. Epelbaum RI, Faraggi D, Ben-Arie Y, et al. Survival of diffuse large cell lymphoma: a multivariate analysis including dose intensity variables. Cancer 1990; 66: 1124-9.
24. Kwak LW, Halper J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963-77.
25. Lepage E, Gisselbrecht C, Sebban HC, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. Ann Oncol 1993; 4: 651-6.
26. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430-6.
27. Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF): a review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991; 42: 300-30.
28. Beveridge RA, Miller JA, Kales AN, et al. Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy. Support Care Cancer 1997; 5: 289-98.
29. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-7.
30. Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized in the peripheral blood of normal donors by GM-CSF or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-82.
31. Engelhard M. First experiences and perspectives for the use of cytokines in the treatment of non-Hodgkin's lymphoma. Anti-Cancer Drugs 1993; 4 (suppl 1): 21-5.
32. Gilewski TA, Richards JM. Biologic response modifiers in non-Hodgkin's lymphomas. Semin Oncol 1990; 17: 74-87.
33. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993; 329: 1608-41.
34. Foon KA, Roth MS, Bunn PA Jr. Alpha interferon treatment of low grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia. Semin Oncol 1986; 13 (suppl 2): 35-42
35. Gaynor ER, Fisher RI. Clinical trials of alpha-interferon in the treatment of non-Hodgkin's lymphoma. Semin Oncol 1991; 18 (suppl 7): 12-17.
36. O'Connell MJ, Colgan JP, Oken MM, Ritts RE Jr, Kay NE, Itri LM. Clinical trial of recombinant leukocyte alpha interteron as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1986; 4: 128-36.
37. Ziegler-Heitbrock HWL, Schlag R, Flieger D, et al. Favourable response of early stage B-CLL patients to treatment with IFN-α2. Blood 1989; 73: 1426-30.
38. Clark RH, Dimitrov NV, Axelson JA, Charamella LJ, Scott PB. A phase II trial of intermittent leukocyte interferon and high dose chlorambucil in the treatment of non-Hodgkin's lymphoma resistent to conventional therapy. Am J Clin Oncol 1989; 12: 75-7.
39. Rohatiner AZS, Richards MA, Barnett MJ, Stansfeld AG, Lister TA. Chlorambucil and interferon tor low grade non-Hodgkin's lymphoma. Br J Cancer 1987; 55: 225-6.
40. Gilewski TA, Richards JM. Biologic response modifiers in non-Hodgkin's lymphomas. Semin Oncol 1990; 17: 74-87.
41. Margolin KA, Aronson FR, Sznol M, et al. Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J Immunother 1991; 10: 214-20.
42. Tourani JM, Levy V, Briere J, et al. Interleukin-2 therapy for refractory and relapsing lymphomas. Eur J Cancer 1991; 27: 1676-80.
43. Laura F, Raspadori D, Ventura MA, et al. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 79-85.
44. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994; 84: 964-71.
45. Fibbe WE, Raemaekers J, Verdonck LF, et al. Recombinant human interleukin-3 after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1991; 78 (suppl): 163a.
46. Hovgaard DJ, Nissen NI. Effects of interleukin-3 following chemotherapy of non-Hodgkin's lymphoma. A prospective, controlled phase I/II study. Eur J Haematol 1995; 54: 78-84.
47. Vose JM, Anderson JE, Bierman PJ, et al. Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy. J Clin Oncol 1996; 14: 520-6.
48. Vose JM, Pandite AN, Beveridge RA, et al. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial. J Clin Oncol 1997; 15: 1617-23.
49. Martelli M, Vignetti M, Zinzani PL, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996; 14: 534-42.
50. Dumontet C, Bastion Y, Felman P, et al. Long term outcome and quality of life in agressive lymphoma patients treated with the LNH-80 regimen. Ann Oncol 1992; 3: 639-44.
51. Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757-65.
52. Cabanillas F, Hagemeister FB, McLaughlin P, et al. Results of MIME salvage regimen for recurrent of refractory lymphoma. J Clin Oncol 1987; 5: 407-12.
53. Freedman AS, Takvorian T, Anderson KC, et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784-91.
54. Koppler H, Pfluger KH, Klausmann M, Havemann K. High-dose cyclophosphamide, etoposide, and BCNU with non-cryopreserved autologous bone marrow transplantation for poor prognosis malignant lymphoma. Leuk Lymphoma 1992; 6: 219-25.
55. Vose JM, Anderson JR, Kessinger A, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-51.
56. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-7.
57. Jones RJ, Ambinder RF, Piantadosi S, et al. Evidence of a graft-versus-lymphoma effect assiciated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-53.
58. Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-5.
59. Appelbaum FR, Sullivan KM, Buckner CD, et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340-5.
60. Van Besien K, Rowlings PA, Sobocinski KA, et al. Allogeneic bone marrow transplantation for low grade lymphoma. Blood 1995; 86: 824a.
61. Vose JM, Armitage JO. Role of autologous bone marrow transplantation in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 1993; 7: 577-90.
62. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotheapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
63. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-8.
64. Vose J, Bierman PJ, Anderson JR, et al. High-dose chemotherapy with hematopoietic stem cell rescue for non-Hodgkin's lymphoma: evaluation of event-free survival based on hisologic subtype and rescue product. Proc Am Soc Clin Oncol 1992; 11: 108a.
65. Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1131-7.
66. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Eng J Med 1997; 336: 1290-7.
67. Verdonck LF, van Putten WL, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Eng J Med 1995; 332: 1045-51.
68. Martelli M, Vignetti M, Zinzani PL, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. Clin Oncol 1996; 14: 534-42.
69. Uyl-de Groot CA, Hagenbeek A, Verdonck LF, Lowenberg B, Rutten FF. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate-and high-grade malignant non-Hodgkin's lymphoma. Bone Marrow Transplant 1995; 16: 463-70.
70. Torrance GW, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics 1996; 9: 535-59.
71. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies: recommendations from the panel on cost effectiveness in health and medicine. Pharmecoeconomics 1997; 11: 159-68.
72. Coiffier B, Philip T, Burnett AK, Symann ML. Consensus conference on intensive chemotherapy plus hematopoietic stem-cell transplantation in malignancies: Lyon, France, June 4-6, 1993. J Clin Oncol 1994; 12: 226-31.
73. Pott-Hoeck C, Hiddemann W. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 1995; 6: 421-33.
74. Hiddemann W, Unterhalt M, Pott C, Wormann B, et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin Oncol 1993; 20 (suppl 7): 28-31.
75. Hiddemann W, Pott-Hoeck C. Fludarabine in the management of malignant lymphomas. Drugs 1994; 47 (suppl 6): 50-6.
76. Zinzani PL, Bendandi M, Magagnoli M, Gherlinzoni F, Merla E, Tura S. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol 1997; 8: 379-83.
77. Kaminski MS, Zasadny KR, Frances IR, et al. Radioimmunotherapy of B-cell lymphoma with 131-1 anti-Bi antibody. N Engl J Med 1993; 329: 459-65.
78. Dupont J, Pavlovsky S, Woolley P, et al. A comparison of two chemotherapy regimens, C-MOPP and BACOP, for the treatment of diffuse mixed and histiocytic lympho mas. Proc Am Soc Clin Oncol 1983; 2: 215.
79. O'Connell M, Anderson J, Earle J, Johnson G, Harrington D, Glick J. Combined modality therapy of advanced unfavorable non-Hodgkin's lymphoma: an ECOG randomized clinical trial. Proc Am Soc Clin Oncol 1984; 3: 241.
80. Hagberg H, Bjorkholm M, Glimelius B, Lindemalm CH, Mellstedt H, Killander A. CHOP vs. MEV for the treatment of non-Hodgkin's lymphoma of unfavourable histopathology: a randomized clinical trial. Eur J Cancer Clin Oncol 1985; 21: 175-9.
81. Cooper IA, Ding JC, Mattherws JP, et al. A randomized comparison of MACOP-B and CHOP in intermediate grade non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1991; 10: 271
82. Garcia-Conde J, Vinolas N, Estape J. ProMACE-CytaBOM vs CHOP in the treatment of unfavourable lymphomas: a randomized trial. Blood 1991; 78 (suppl): 127a.
83. Tura S, Zinzani PL, Mazza P, et al. F-MACHOP versus MACOP-B in the treatment of high grade malignant non-Hodgkin's lymphoma. Blood 1991; 78 (suppl): 109a.
84. Longo DL, De Vita VT Jr, Duffey PL, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991; 9: 25-38.
85. Gherlinzoni F, Guglielmi C, Mazza P, Amadori S, Mandelli F, Tura S. Phase III comparative trial (m-BACOD vs. m-BNCOD) in the treatment of Stage II to IV non-Hodgkin's lymphomas with intermediate or high grade histology. Semin Oncol 1990; 17 (suppl 10): 3-9.
86. Federico M, Moretti G, Gobbi PG, et al. ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL: preliminary results of a prospective randomized trial. Leukemia 1991; 5: 95-101.
87. Cabanillas F, Hagemeister FB, Bodey G, et al. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693-7.
88. Valesquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-22.
89. Valesquez WS, Hagemeister F, McLaughlin P, et al. ESHAP: an effective treatment for refractory and relapsing lymphoma. A long follow-up. Proc Am Soc Clin Oncol 1992; 11: 326.
90. Chao NJ, Rosenberg SA, Homing SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk aggressive non-Hodgkin's lymphoma. Blood 1990; 76: 1293-8.
91. Silver RT, Case DC Jr, Wheeler RH, et al. Multicenter clinical trial of mitoxanthrone in non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 1991; 9: 754-61.
92. Herbrecht R, Coiffier B, Tilly H, et al. Mitoxantrone, ifosfamide and etoposide (MIV) in aggressive lymphomas failing treatment with the LNH-87 regimen. Proc Am Soc Clin Oncol 1991; 10: 278.
93. Toner GC, Laidlaw C, Millward MJ, et al. Low versus standard dose prophylactic G-CSF after chemotherapy, a randomized cross over comparison. Blood 1994; 10 (suppl 1): 84
94. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551-73.